Vision is one of our most important senses. It has always been vital, and is even more so in today's, "visual information age." Even mobile phones, formerly the quintessential auditory devices, have become more visual tools. Loss of vision is the number one fear when it comes to age-related health matters. Even moderate visual problems can significantly reduce a person’s productivity, mobility and independence.
As a specialised pharmaceutical company engaged in the ophthalmic field, Santen has established key position in Japan's prescription ophthalmic pharmaceutical market and has now expanded into the global market. Santen has been present in Europe for nearly 20 years and is continuing to strengthen its position in the European area, enabling more patients and health care professionals to have access to our innovative treatments.
We have the ambition to become a European leader in ophthalmology.
Our priority is to develop and acquire new and better solutions that respond to the needs of both patients and healthcare professionals. Santen’s activities primarily focus on ocular surface disorders including dry eye, glaucoma, retina and certain orphan eye diseases.
Research-based, Santen is dedicated to develop innovative therapeutic solutions to treat eye diseases in its four research centres based in Japan, USA, Finland and France.